Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Longchuan Bai

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Journal of Medicinal Chemistry|April 8, 2025
Correction to "Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer"Ranjan Kumar Acharyya, Rohan Kalyan Rej, Biao Hu, et al.
Cancer Research|August 23, 2014
SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regressionShaomeng Wang, Wei Sun, Yujun Zhao, et al.
Journal of Medicinal Chemistry|November 1, 2024
Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast CancerRanjan Kumar Acharyya, Rohan Kalyan Rej, Biao Hu, et al.
Journal of Medicinal Chemistry|November 25, 2024
Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα)Rohan Kalyan Rej, Biao Hu, Zhixiang Chen, et al.
Nature|May 14, 2025
STAT5 and STAT3 balance shapes dendritic cell function and tumour immunityJiajia Zhou, Kole Tison, Haibin Zhou, et al.
Science Advances|May 1, 2021
Topography of transcriptionally active chromatin in glioblastomaLiang Xu, Ye Chen, Yulun Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2022
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic MalignancyJing Deng, Aneel Paulus, Douglas D Fang, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Journal of Medicinal Chemistry|April 8, 2025
Correction to "Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer"Ranjan Kumar Acharyya, Rohan Kalyan Rej, Biao Hu, et al.
Cancer Research|August 23, 2014
SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regressionShaomeng Wang, Wei Sun, Yujun Zhao, et al.
Journal of Medicinal Chemistry|November 1, 2024
Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast CancerRanjan Kumar Acharyya, Rohan Kalyan Rej, Biao Hu, et al.
Journal of Medicinal Chemistry|November 25, 2024
Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα)Rohan Kalyan Rej, Biao Hu, Zhixiang Chen, et al.
Nature|May 14, 2025
STAT5 and STAT3 balance shapes dendritic cell function and tumour immunityJiajia Zhou, Kole Tison, Haibin Zhou, et al.
Science Advances|May 1, 2021
Topography of transcriptionally active chromatin in glioblastomaLiang Xu, Ye Chen, Yulun Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2022
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic MalignancyJing Deng, Aneel Paulus, Douglas D Fang, et al.
Pageof 7